Eton Pharmaceuticals, Inc.
ETON
Rank in Stocks
#6208
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and... Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Share Price
$64.35
Last synced: 2026-11-09
Market Cap
$1.84B
Change (1 day)
13.97%
Change (1 year)
264.38%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Eton Pharmaceuticals, Inc. (ETON)
Category
Healthcare
EPS for Eton Pharmaceuticals, Inc. (ETON)
EPS as of September 2026 TTM: $1.77
According to Eton Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $1.77. At the end of 2025 the company had an EPS of $-0.17, a decrease compared to its 2024 EPS of $-0.15.
EPS history for Eton Pharmaceuticals, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $1.77 | -1,141.18% |
| 2025 | $-0.17 | 13.33% |
| 2024 | $-0.15 | 310.96% |
| 2023 | $-0.04 | -89.86% |
| 2022 | $-0.36 | 363.92% |
| 2021 | $-0.08 | -94.17% |
| 2020 | $-1.33 | 30.39% |
| 2019 | $-1.02 | -48.74% |
| 2018 | $-1.99 | 385.37% |
| 2017 | $-0.41 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 267.31% |
DE
|
|
| $6.08 | 243.37% |
DE
|
|
| $1.55 | -12.40% |
JP
|
|
| $3.66 | 106.78% |
CH
|
|
| $0.45 | -74.58% |
IL
|
Questions about Eton Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Eton Pharmaceuticals, Inc.'s earnings per share (EPS)?
Eton Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $1.77, as of Sep 2026.
What was Eton Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Eton Pharmaceuticals, Inc.'s earnings per share (EPS) was $-0.17, compared with $-0.15 in 2024.
How has Eton Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Eton Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2023 ($-0.04) and lowest in 2020 ($-1.33).
How does Eton Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Eton Pharmaceuticals, Inc.'s earnings per share (EPS) ($1.77) is higher than that of 2 of the 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.